ANALIZE MEDICALE DE LABORATOR
Aici gasiti analizele medicale grupate pe categorii precum si detalii generale si specifice pentru categoriile respective.
Selectati o categorie din lista de mai jos:
Solutie antistress!
Construieste poduri :)
Prinde pisica neagra :)
Inverseon Announces Positive Phase IIa Asthma Study
In the article by Hanania et al., in Pulmonary Pharmacology &
Therapeutics, vol. 21, (2008), pp. 134-141, entitled, "The safety and
effects of the beta-blocker, nadolol, in mild asthma: An open-label pilot
study," mild asthmatics were treated for 9 weeks. All subjects tolerated
the drug, and 8 of 10 subjects experienced a clinically meaningful,
dose-related, reduction in airway hyper-responsiveness.
"To our knowledge, this is the first peer-reviewed publication of a
clinical trial testing a beta-blocker for the treatment of asthma,"
commented Richard Bond, PhD, Scientific Founder of Inverseon. "These
results lay the groundwork for continuing safety and efficacy studies for a
drug that is normally withheld from asthmatics. A similar story played out
10 years ago in congestive heart failure where certain blocker drugs that
were once contraindicated are now on the market as the best drugs we have
ever had at decreasing mortality in heart failure."
"From receptor theory to animal data and now to clinical data the
Inverseon approach is very consistent. In our animal asthma models chronic
dosing of beta inverse agonists -- which are a subset of beta blockers --
resulted in up-regulation of lung beta receptors, while reducing
inflammation and airway hyper-responsiveness. The fact that we are seeing
some of these same changes in human asthmatic subjects is exciting and
suggests we may have a way to counteract some of the negative aspects of
long-acting beta-agonists and steroids when used in combination with
INV102. The data also supports Inverseon's reformulation program for oral
controlled-release INV102," commented William J. Garner, MD, Chairman of
Inverseon.
About Inverseon, Inc.
Inverseon's product development programs target significant unmet
medical needs and major market opportunities in chronic pulmonary diseases
such as asthma, COPD and pulmonary hypertension. Inverseon was founded
based on the original work of Prof. Richard Bond of the University of
Houston. Professor Bond termed the effects "Paradoxical Pharmacology,"
based on the divergence of acute versus chronic effects of certain drugs in
chronic diseases. For further information, please visit Inverseon's website
at http://www.inverseon.com.
Forward-Looking Statement
This press release may contain forward-looking statements. In some
cases, you can identify forward-looking statements by terminology such as
"may," "will," "should," "expect," "plan," "anticipate," "believe,"
"estimate," "predict," "potential" or "continue," the negative of such
terms, or other comparable terminology. These statements are only
predictions. Although we believe that the expectations reflected in the
forward-looking statements are reasonable, such statements should not be
regarded as a representation by the Company, or any other person, that such
forward-looking statements will be achieved. We undertake no duty to update
any of the forward-looking statements, whether as a result of new
information, future events, or otherwise. In light of the foregoing,
readers are cautioned not to place undue reliance on such forward-looking
statements.
Inverseon, Inc.
http://www.inverseon.com
Inverseon anunta pozitiv faza studiu IIa astm - Inverseon Announces Positive Phase IIa Asthma Study - articole medicale engleza - startsanatate